Skip to main content
SpringerLink
Log in
Book cover

Radiopharmaceuticals pp 211–225Cite as

68Ga-PSMA

  • Chapter
  • First Online:

  • 955 Accesses

Abstract

Imaging prostate cancer and metastases either by morphologic radiological approach or nuclear medicine methods has not fulfilled the expectations of the clinicians until several years. PSMA—prostate-specific membrane antigen—which can be labeled with positron-emitting isotopes mostly 68Ga—changed this setting substantially. Prostate cancer is the most common tumor entity in men worldwide and the third leading cause of cancer-related death in men in Europe and the USA. Biochemical relapse is a frequent event after primary therapy. A large body of evidence is available for restaging of prostate cancer patients with biochemical recurrence. 68Ga-PSMA PET/CT demonstrates high detection rates in patients with biochemical recurrence of prostate cancer after primary radiation therapy as well as after radical prostatectomy. 68Ga-PSMA PET has also been used for radiotherapy planning. Compared to conventional CT, PSMA PET/CT had a remarkable impact on radiotherapeutic approach especially in postoperative patients. PSMA is an ideal structure for both imaging and targeted therapy for prostate cancer, therefore enabling a theranostic approach.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

18F-DCFBC:

(N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-F-fluorobenzyl-l-cysteine)

18F-DCFPyL:

2-(3-{1-carboxy-5-[(6-[(18)F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid

18F-FDG:

18F-Fluorodeoxyglucose

18F-FET:

18F-Fluoroethylthirosine

68Ga-PSMA:

68Ga-prostate-specific membrane antigen

DOTAtaGA:

(1,4,7,10-tetraazacyclododecane-1-(1-carboxy-3-carbo-tertbutoxypropyl)-4,10 (carbotertbutoxymethyl)-7-acetamide)

PET/CT:

Positron emission tomography/ computed tomography

PET/MRI:

Positron emission tomography/magnetic resonance imaging

PSA:

Prostate-specific antigen

References

  1. Nanabala R, Anees MK, Sasikumar A, et al. Preparation of [(68)Ga]PSMA-11 for PET-CT imaging using a manual synthesis module and organic matrix based (68)Ge/(68)Ga generator. Nucl Med Biol. 2016;43:463–9.

    Article  CAS  PubMed  Google Scholar 

  2. Giovacchini G, Giovannini E, Riondato M, et al. PET/CT with 68Ga-PSMA in prostate cancer: radiopharmaceutical background and clinical implications. Curr Radiopharm. 2018;11:4–13.

    Article  CAS  PubMed  Google Scholar 

  3. Afshar-Oromieh A, Babich JW, Kratochwil, et al. The rise of PSMA ligands for diagnosis and therapy of prostate cancer. J Nucl Med. 2016;57:79S–89S.

    Article  CAS  PubMed  Google Scholar 

  4. Sheikhbahaei S, Afshar-Oromieh A, Eiber M, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44:2117–36.

    Article  PubMed  Google Scholar 

  5. Lenzo NP, Meyrick D, Turner JH, et al. Review of gallium-68 PSMA PET/CT imaging in the management of prostate cancer. Diagnostics (Basel). 2018;11, 8

    Google Scholar 

  6. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–74.

    Article  PubMed  Google Scholar 

  7. Jadvar H. PSMA PET in prostate cancer. J Nucl Med. 2015;56:1131–2.

    Article  CAS  PubMed  Google Scholar 

  8. Salas Fragomeni RA, Amir T, Sheikhbahaei S, et al. Imaging of nonprostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms. J Nucl Med. 2018;59:871–7.

    Article  PubMed  Google Scholar 

  9. Ceci F, Uprimny C, Nilica B, et al. 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42:1284–94.

    Article  PubMed  Google Scholar 

  10. Freedland SJ, Presti JC Jr, Amling CL, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003;61:736–41.

    Article  PubMed  Google Scholar 

  11. Rayn KN, Elnabawi YA, Sheth N. Clinical implications of PET/CT in prostate cancer management. Transl Androl Urol. 2018;7:844–54.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Grubmüller B, Baltzer P, Hartenbach S, et al. PSMA ligand PET/MRI for primary prostate cancer: staging performance and clinical impact. Clin Cancer Res. 2018;24:6300–7.

    Article  PubMed  Google Scholar 

  13. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209.

    Article  CAS  PubMed  Google Scholar 

  14. Schwarzenboeck SM, Rauscher I, Bluemel C, et al. PSMA ligands for PET imaging of prostate cancer. J Nucl Med. 2017;58:1545–52.

    Article  CAS  PubMed  Google Scholar 

  15. Perera M, Papa N, Roberts M, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2019;. [Epub ahead of print]

    Google Scholar 

  16. Müller J, Ferraro DA, Muehlematter UJ, et al. Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. Eur J Nucl Med Mol Imaging. 2019;6:889–900.

    Article  Google Scholar 

  17. Einspieler I, Rauscher I, Düwel C, et al. Detection efficacy of hybrid 68Ga-PSMA ligand PET/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by phoenix criteria. J Nucl Med. 2017;58:1081–7.

    Article  CAS  PubMed  Google Scholar 

  18. Schmidt-Hegemann NS, Fendler WP, Ilhan H, et al. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. Radiat Oncol. 2018;13:37.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Calais J, Czernin J, Cao M, et al. 68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med. 2018;59:230–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Calais J, Czernin J, Fendler WP, et al. Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer. 2019;19:97.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Heinzel A, Boghos D, Mottaghy FM, et al. 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1054–62.

    Article  CAS  PubMed  Google Scholar 

  22. Weineisen M, Schottelius M, Simecek J, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169–76.

    Article  CAS  PubMed  Google Scholar 

  23. Sathekge M, Bruchertseifer F, Knoesen O, et al. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46:129–38.

    Article  CAS  PubMed  Google Scholar 

  24. Kesavan M, Turner JH, Meyrick D, et al. Salvage radiopeptide therapy of advanced castrate-resistant prostate cancer with lutetium-177-labeled prostate-specific membrane antigen: efficacy and safety in routine practice. Cancer Biother Radiopharm. 2018;33:274–81.

    Article  CAS  PubMed  Google Scholar 

  25. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20.

    Article  CAS  PubMed  Google Scholar 

  26. Lütje S, Heskamp S, Cornelissen AS, et al. PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status. Theranostics. 2015;5:1388–401.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Parent EE, Schuster DM. Update on 18F-fluciclovine PET for prostate cancer imaging. J Nucl Med. 2018;59:733–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. England JR, Paluch J, Ballas LK, et al. 18F-fluciclovine PET/CT detection of recurrent prostate carcinoma in patients with serum PSA ≤ 1 ng/mL after definitive primary treatment. Clin Nucl Med. 2019;44:e128–32.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Andriole GL, Kostakoglu L, Chau A, et al. The impact of positron emission tomography with 18F-fluciclovine on the treatment of biochemical recurrence of prostate cancer: results from the LOCATE trial. J Urol. 2019;201:322–31.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Koerber SA, Will L, Kratochwil C, et al. 68Ga-PSMA-11 PET/CT in primary and recurrent prostate carcinoma: implications for radiotherapeutic management in 121 patients. J Nucl Med. 2019;60(2):234–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Rauscher I, Maurer T, Fendler WP, et al. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: how we review and report. Cancer Imaging. 2016;16:14.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Afshar-Oromieh A, Sattler LP, Mier W, et al. The clinical impact of additional late PET/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J Nucl Med. 2017;58:750–5.

    Article  CAS  PubMed  Google Scholar 

  33. Krohn T, Verburg FA, Pufe T, et al. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42:210–4.

    Article  PubMed  Google Scholar 

  34. Strele-Trieb P, Dunzinger A, Sonnberger M, et al. Uptake of 68Ga-prostate-specific membrane antigen pet in adrenal gland: a potential pitfall. Clin Nucl Med. 2018;43:50–1.

    Article  PubMed  Google Scholar 

  35. Calabria F, Gangemi V, Gullà D, et al. 64Cu-PSMA uptake in meningioma: a potential pitfall of a promising radiotracer. Rev Esp Med Nucl Imagen Mol. 2017;36:335–6.

    CAS  PubMed  Google Scholar 

  36. Kesler M, Levine C, Hershkovitz D, et al. 68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: a prospective pilot study. J Nucl Med. 2018;. [Epub ahead of print]

    Google Scholar 

  37. Backhaus P, Noto B, Avramovic N, et al. Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. Eur J Nucl Med Mol Imaging. 2018;45:860–77.

    Article  CAS  PubMed  Google Scholar 

  38. Nomura N, Pastorino S, Jiang P, et al. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int. 2014;14:26.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Nuclear Medicine, Kepler University Hospital, Neuromed Campus, Linz, Austria

    Robert Pichler & Andreas Dunzinger

  2. Institute of Nuclear Medicine, General Hospital Steyr, Steyr, Austria

    Robert Pichler

  3. Department of Radiology, Clinic of Nuclear Medicine, Medical University Graz, Graz, Austria

    Robert Pichler

  4. Department of Urology, General Hospital Steyr, Steyr, Austria

    Johannes Wolfsgruber

  5. Department of Nuclear Medicine and Theranostics, “Mariano Santo” Hospital, Cosenza, Italy

    Ferdinando Calabria

  6. Department of Biomedicine and Prevention, University “Tor Vergata”, Rome, Italy

    Orazio Schillaci

  7. Department of Nuclear Medicine and Molecular Imaging, IRCCS INM Neuromed, Pozzilli, IS, Italy

    Orazio Schillaci

Authors
  1. Robert Pichler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes Wolfsgruber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ferdinando Calabria
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Orazio Schillaci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andreas Dunzinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Pichler .

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine and Theranostics, Mariano Santo Hospital, Cosenza, Italy

    Ferdinando Calabria

  2. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

    Orazio Schillaci

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pichler, R., Wolfsgruber, J., Calabria, F., Schillaci, O., Dunzinger, A. (2020). 68Ga-PSMA. In: Calabria, F., Schillaci, O. (eds) Radiopharmaceuticals. Springer, Cham. https://doi.org/10.1007/978-3-030-27779-6_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-27779-6_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-27778-9

  • Online ISBN: 978-3-030-27779-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation